Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 10

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 10
---
,184,733 of Shares, consisting of $3,684,733
remaining of the amount originally registered and the additional $4,500,000 increase under the Prospectus Supplement.

The
Company sold 5,932 shares of common stock under the ATM Agreement for net proceeds of $99,506 during 2024. During 2025, the Company sold 551,265 shares
of common stock under the ATM Agreement for net proceeds of $3,638,767 through September 30, 2025. The Company sold 174,081 shares of common stock under the ATM Agreement for net proceeds of $816,030 subsequent
to September 30, 2025.

July
2024 Offering

On
July 30, 2024, the Company entered into the July 2024 Purchase Agreement with the Purchasers, pursuant to which the Company issued, in
a registered direct offering, an aggregate of 333,334 shares of the Company’s common stock at an offering price of $30.00 per share
for gross proceeds of $10.0 million before the deduction of placement agent fees and offering expenses. In a concurrent private placement
and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers the Warrants to purchase an aggregate of
333,334 shares of its common stock at an exercise price of $30.00 per share.

The
Warrants became exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing
of the July 2024 Offering occurred on August 1, 2024.

    13

On
May 12, 2025, the Company entered into an exchange agreement (the “Agreement”) with the holders (the “Warrant Holders”)
of certain warrants of the Company issued on August 1, 2024, which are exercisable for an aggregate of 333,334 shares of the Company’s
common stock, par value $0.01 per share. Pursuant to the terms of the Agreement, the Company will issue to the Warrant Holders an aggregate
of 194,734 shares of Common Stock (the “Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable
under the Warrants (the “Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of
the Securities Act of 1933, as amended (the “